Your session is about to expire
← Back to Search
Aurora Kinase Inhibitor
PHA-739358 for Chronic Myelogenous Leukemia
Phase 2
Waitlist Available
Research Sponsored by Jonsson Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Chronic, accelerated, or blastic phase disease
ECOG performance status 0-2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Study Summary
This trial is testing a drug to see if it can stop the growth of cancer cells in people with leukemia who have relapsed after other treatments.
Who is the study for?
This trial is for patients with chronic myelogenous leukemia who have relapsed after treatment with imatinib mesylate or c-ABL therapy. Participants must not have central nervous system leukemia, HIV, significant cardiovascular issues within the last 6 months, or major thromboembolic events. They should have normal organ function tests and agree to use effective contraception during and after the study.Check my eligibility
What is being tested?
The trial is testing PHA-739358's effectiveness in stopping cancer cell growth by blocking certain enzymes needed for their proliferation. This phase II study aims to determine how well it works for those whose leukemia has returned despite previous treatments.See study design
What are the potential side effects?
While specific side effects of PHA-739358 are not listed here, similar cancer drugs can cause fatigue, nausea, liver problems, blood disorders, increased risk of infection and heart complications among other potential side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My condition is in a chronic, accelerated, or blast phase.
Select...
I can take care of myself and perform daily activities.
Select...
My leukemia diagnosis was confirmed with a bone marrow test.
Select...
My condition worsened after treatment with imatinib or c-ABL therapy.
Select...
I have not had severe bleeding.
Select...
I haven't had a major blood clot or heart attack in the last 6 months.
Select...
I do not have HIV.
Select...
I do not have any ongoing infections that aren't under control.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Antileukemic response in terms of complete hematological response, no evidence of leukemia, or return to chronic phase
Changes in histone H3 and CRKL phosphorylation
Complete, partial, or minor cytogenetic response in bone marrow
+3 moreFind a Location
Who is running the clinical trial?
Jonsson Comprehensive Cancer CenterLead Sponsor
359 Previous Clinical Trials
26,059 Total Patients Enrolled
21 Trials studying Leukemia
205 Patients Enrolled for Leukemia
National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,933,137 Total Patients Enrolled
1,512 Trials studying Leukemia
384,666 Patients Enrolled for Leukemia
Ronald Paquette, MDStudy ChairJonsson Comprehensive Cancer Center
5 Previous Clinical Trials
86 Total Patients Enrolled
3 Trials studying Leukemia
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am not currently on any other cancer treatments.My condition is in a chronic, accelerated, or blast phase.I can take care of myself and perform daily activities.I will stop taking hydroxyurea one day before starting the study treatment.I haven't had serious heart problems like uncontrolled irregular heartbeats or chest pain in the last 6 months.My leukemia diagnosis was confirmed with a bone marrow test.My condition worsened after treatment with imatinib or c-ABL therapy.It has been over 2 weeks since my last chemoimmunotherapy session.I have not had severe bleeding.I do not have HIV.I haven't had a major blood clot or heart attack in the last 6 months.I do not have any ongoing infections that aren't under control.My leukemia may have a specific genetic change (T315I mutation).I do not have leukemia in my brain or spinal cord.It has been over 4 weeks since my last major surgery.I am using birth control during and after the study as required.I have recovered from side effects of my previous treatment, except for hair loss.
Research Study Groups:
This trial has the following groups:Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are researchers still enrolling new participants for this trial?
"This particular clinical trial is not looking for patients at the moment, as evidenced by its listing on clinicaltrials.gov. The trial was first posted on March 1st 2007 and updated December 17th 2013. Although this isn't an option right now, there are 1507 other trials that are presently recruiting participants."
Answered by AI
Are there any harmful side effects associated with this treatment?
"Given that this is a Phase 2 trial, where there is some clinical data supporting safety but none for efficacy, our team scores the risk at a 2."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger